BofA Finance LLC has filed a pricing supplement for its new contingent income buffered auto-callable yield notes linked to the common stock of Blackstone Inc. This filing, dated November 5, 2026, indicates the company’s ongoing strategy to expand its range of financial products.
The notes are designed to provide investors with a contingent coupon rate of 10.00% per annum, payable monthly if certain conditions are met. This structured product aims to attract investors looking for innovative investment solutions in a competitive market.
Background
BofA Finance LLC, a subsidiary of Bank of America Corporation, operates within the national commercial banks sector (SIC: 6021). The company is incorporated in Delaware and is based in Charlotte, North Carolina. This filing follows several recent submissions on the same date, emphasizing the company’s active engagement in financial markets.
What the Filing Says
The pricing supplement details that the notes are expected to price on November 19, 2026, and will be issued on November 24, 2026. It states, “Payments on the Notes will depend on the performance of the common stock of Blackstone Inc.” This highlights the notes' reliance on the underlying asset's market performance.
Impact
This development may affect a variety of stakeholders, including investors seeking structured products and competitors within the national commercial banking sector. The contingent income feature of the notes could attract a specific segment of investors, thereby enhancing BofA Finance’s competitive position in the market.
What's Next
Following this filing, the next steps include the pricing and issuance of the notes, as outlined in the filing. Investors will be closely watching the performance of the underlying stock and the terms of the notes as they approach the pricing date.
Read Next
Meridian Growth Collective Launches Crowdfunding Offering
UBS AG Files Preliminary Pricing Supplement for Notes
New Residential Funding Releases Third-Party Due Diligence Report
Brunswick Corp. Officer David Foulkes Sells 48,134 Shares
Fate Therapeutics Announces $100 Million Common Stock Offering
SAM Alternative Investment Opportunities Fund III files new D




